Novo says Ozempic succeeded in late-stage trial for peripheral artery disease
Novo Nordisk (NVO) says its obesity drug Ozempic improved walking distance for diabetes patients with peripheral artery ...
The Woodlands-based company strikes obesity-drug license deal worth up to $1B
Lexicon Pharmaceuticals Inc. said March 28 it will exclusively license its drug candidate LX9851 to Danish pharmaceutical ...
SA Asks: What are the best large-cap cardiology stocks right now?
Developers of cardiology drugs and devices will be back in the spotlight this weekend when the annual scientific meeting of ...
Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...